Leerink Swann Downgrades Auxilium Pharmaceuticals (AUXL) to Market Perform

Go back to Leerink Swann Downgrades Auxilium Pharmaceuticals (AUXL) to Market Perform

Auxilium Pharma (AUXL) to Present Positive Data from AUX-CC-867 MULTICORD Phase 3b

September 18, 2014 7:02 AM EDT

Auxilium Pharma (Nasdaq: AUXL) announced the first presentation of positive safety and efficacy data from the AUX-CC-867 MULTICORD (MULtiple Treatment Investigation of Collagenase Optimizing the Resolution of Dupuytrens) Phase 3b study. This study evaluated collagenase clostridium histolyticum (CCH) for the treatment of two Dupuytren's cords concurrently in the same hand. In addition, the study examined expanded flexibility with timing of the finger extension procedure. Additional positive data were presented from the AUX-CC-862 retreatment study that evaluated the retreatment of recurrent contracture in joints that... More

Endo (ENDP) Makes $28.10/Share Bid for Auxilium Pharma (AUXL)

September 16, 2014 4:45 PM EDT

Endo International plc (Nasdaq: ENDP) announced that it has delivered a proposal to acquire all of the outstanding shares of Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) for a per share consideration of $28.10 in a cash and stock transaction valued at $2.2 billion.

Endo's proposal represents a premium of 31% to Auxilium's closing price on September 16, 2014 and a 40% premium to the average closing price of Auxilium shares for the previous 30 days. Under the terms of the proposal, the consideration would include an approximately equal mix of cash and Endo... More